Canvass Clinical Research Services Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-07-2024
- Paid Up Capital ₹ 0.10 M
as on 25-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 68.06%
(FY 2023)
- Profit 179.36%
(FY 2023)
- Ebitda 324.19%
(FY 2023)
- Net Worth 106.28%
(FY 2023)
- Total Assets 149.54%
(FY 2023)
About Canvass Clinical Research Services
The Company is engaged in the Education Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Nishad, Mangal Bhakte, Jaya Mishra, and One other member serve as directors at the Company.
- CIN/LLPIN
U73100MH2019PTC321831
- Company No.
321831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Canvass Clinical Research Services?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijaya Bhakte  | Director | 25-Feb-2019 | Current |
| Anand Nishad | Additional Director | 25-Jul-2024 | Current |
| Mangal Bhakte | Director | 20-Mar-2021 | Current |
| Jaya Mishra | Additional Director | 25-Jul-2024 | Current |
Financial Performance of Canvass Clinical Research Services.
Canvass Clinical Research Services Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.06% increase. The company also saw a substantial improvement in profitability, with a 179.36% increase in profit. The company's net worth Soared by an impressive increase of 106.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Canvass Clinical Research Services?
In 2023, Canvass Clinical Research Services had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Schwandt Ujagare Alternative Medicine Private LimitedActive 7 years 8 monthsAnand Nishad is a mutual person
- Briminc Saarthi Advisory And Consulting Private LimitedActive 1 month 10 days
Jaya Mishra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Canvass Clinical Research Services?
Unlock and access historical data on people associated with Canvass Clinical Research Services, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Canvass Clinical Research Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Canvass Clinical Research Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
